{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:18:53Z","timestamp":1784600333111,"version":"3.55.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>There is increasing evidence that many endometrial cancers (EC) diagnosed as clear cell carcinoma (CCC) have substantial overlap with both serous carcinoma (SC) and endometrioid carcinoma (EmC), not only in terms of morphology and immunophenotype but also by molecular characterization. Now with use of HER2-based therapy in SC, a CCC diagnosis in serous-like tumors has the potential to exclude patients from receiving beneficial therapy. To assess HER2 in CCC in relation to other characteristics, a tissue microarray of archived CCC, EmC, and SC was stained for HER2 alongside a battery of immunostains used in EC. Cases with equivocal HER2 IHC were also assessed by <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization. HER2 status was assessed in 229 cases (23 CCC, 74 SC, 132 EmC). HER2 was positive in 48% of cases diagnosed as CCC, 19% of SC, and 0% of EmC. Rigorous morphologic and immunophenotypic review by 5 gynecologic pathologists revealed diagnostic disagreement in 8\/11 HER2+ cases diagnosed as CCC, with SC as the other major diagnostic consideration. All HER2+ (n=25) cases were MMR-intact and most HER2+ EC had aberrant p53 staining (22\/25, 88%); the 3 cases with a wild type pattern for p53 (12%) were all negative for ER. Based on these findings, patients with a diagnosis of CCC should be included in future clinical trials of HER2-targeted therapy. Moreover, given the diagnostic difficulty surrounding CCC, immunohistochemistry-based algorithms that include aberrant p53 and\/or the absence of ER expression may provide a more objective means of establishing eligibility criteria than is currently possible using traditional histologic classification.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000783","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T01:01:03Z","timestamp":1617066063000},"page":"132-141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Alain","family":"Cagaanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradly","family":"Stelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin N.","family":"Rhode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Niaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas","volume":"38","author":"Murali","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1097\/IGC.0000000000000297","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix","volume":"24","author":"Hasegawa","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Modern Pathol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathology"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Archiv Pathol Amp Lab Med"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Modern Pathol"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.2008.108","article-title":"Immunophenotyping of serous carcinoma of the female genital tract","volume":"21","author":"Nofech-Mozes","year":"2008","journal-title":"Modern Pathol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J Natl Compr Canc Ne"},{"key":"R11-20250802","article-title":"HER2 testing in endometrial serous carcinoma","author":"Buza","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics\u2010based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PAS.0000000000000764","article-title":"interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on the Cancer Genome Atlas (TCGA)-based molecular subgroup","volume":"41","author":"Hoang","year":"2017","journal-title":"Am J Surg Pathology"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathology"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"Gallo","year":"2017","journal-title":"Cancer"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/PAS.0b013e31825dd4b3","article-title":"The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists","volume":"36","author":"Fadare","year":"2012","journal-title":"Am J Surg Pathology"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PGP.0000000000000162","article-title":"Endometrial carcinomas with clear cells: a study of a heterogeneous group of tumors including interobserver variability, mutation analysis, and immunohistochemistry with HNF-1\u03b2","volume":"34","author":"Han","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/his.12286","article-title":"Immunohistochemical characterization of prototypical endometrial clear cell carcinoma\u2014diagnostic utility of HNF\u20101\u03b2 and oestrogen receptor","volume":"64","author":"Hoang","year":"2014","journal-title":"Histopathology"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/PGP.0000000000000609","article-title":"Use of immunohistochemical markers (HNF-1\u03b2, Napsin A, ER, CTH, and ASS1) to distinguish endometrial clear cell carcinoma from its morphologic mimics including Arias-Stella Reaction","volume":"39","author":"Ji","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/PGP.0000000000000430","article-title":"Morphologic and immunohistochemical study of clear cell carcinoma of the uterine endometrium and cervix in comparison to ovarian clear cell carcinoma","volume":"37","author":"Ju","year":"2018","journal-title":"Int J Gynecol Pathol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/PGP.0000000000000111","article-title":"Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma?","volume":"34","author":"Bae","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer","volume":"26","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn Pathol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in situ hybridization","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"322","DOI":"10.30699\/IJP.2019.90831.1867","article-title":"Evaluation of HER2\/neu expression in high-grade endometrial carcinoma and its clinicopathological correlation","volume":"14","author":"Sarmadi","year":"2019","journal-title":"Iranian J Pathol"},{"key":"R28-20250802","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","author":"Rottmann","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R29-20250802","first-page":"62","article-title":"HER2 testing in gastric\/gastroesophageal junction adenocarcinomas: unique features of a familiar test","volume":"4","author":"Ross","year":"2011","journal-title":"Gastrointest Cancer Res Gcr"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1634\/theoncologist.2015-0149","article-title":"The therapeutic challenge of targeting HER2 in endometrial cancer","volume":"20","author":"Diver","year":"2015","journal-title":"Oncol"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"081","DOI":"10.23937\/2469-5807\/1510081","article-title":"Is p53 overexpression a predictor of worse outcomes in endometrioid endometrial carcinomas?","volume":"4","author":"Raid","year":"2018","journal-title":"Int J Pathology Clin Res"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:02:18Z","timestamp":1754161338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000783","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}